Wall Street analysts expect that TG Therapeutics Inc (NASDAQ:TGTX) will report earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for TG Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.41). TG Therapeutics also reported earnings per share of ($0.46) in the same quarter last year. The company is scheduled to announce its next earnings results on Thursday, March 14th.
According to Zacks, analysts expect that TG Therapeutics will report full year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.10) to ($1.76). For the next financial year, analysts expect that the business will report earnings of ($1.57) per share, with EPS estimates ranging from ($2.09) to ($0.96). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.12. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%.
Several research firms have issued reports on TGTX. Raymond James lowered TG Therapeutics from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $22.00 to $12.00 in a research note on Tuesday, September 25th. Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of TG Therapeutics in a research note on Monday, November 12th. ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 24th. Finally, LADENBURG THALM/SH SH set a $27.00 target price on TG Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.35.
NASDAQ:TGTX traded down $0.28 on Tuesday, hitting $4.88. The company’s stock had a trading volume of 60,659 shares, compared to its average volume of 1,353,376. The firm has a market capitalization of $443.50 million, a price-to-earnings ratio of -2.60 and a beta of 1.77. TG Therapeutics has a one year low of $4.20 and a one year high of $17.35.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Xact Kapitalforvaltning AB bought a new position in shares of TG Therapeutics during the second quarter worth approximately $139,000. Quantitative Systematic Strategies LLC bought a new position in shares of TG Therapeutics during the second quarter worth approximately $146,000. Birchview Capital LP bought a new position in shares of TG Therapeutics during the second quarter worth approximately $197,000. North Star Investment Management Corp. bought a new position in shares of TG Therapeutics during the second quarter worth approximately $276,000. Finally, Claraphi Advisory Network LLC bought a new position in shares of TG Therapeutics during the third quarter worth approximately $123,000. Institutional investors own 49.76% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Featured Story: How Does the Quiet Period Work?
Get a free copy of the Zacks research report on TG Therapeutics (TGTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.